Skip to main content
SpringerLink
Log in

Chemistry and pharmacology of novel antidepressants

  • Chapter
Antidepressants

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

Depression is a common, recurrent and debilitating condition which carries substantial personal, familial and societal costs. It causes significant suffering, disability and social dysfunction frequently leading to disruption of normal life and work. Depressed patients struggle to recover, often over several months and sometimes even years, and many follow a chronic and remorseless course. The high morbidity is accompanied by a substantial mortality, such that as many as 15% of depressed patients take their own lives. Many more attempt suicide at some time during their lives. The economic impact of depression on society is considerable and is comparable to that of other major disorders such as coronary heart disease. However, depression is often not properly recognised, it exacts costs over a longer period of time and places a particularly heavy burden on employers because of lost productivity. Annual costs have been estimated for the USA at about US $ 44 billion [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER (1993a) The economic burden of depression in 1990. JClin Psych 54: 403–418

    Google Scholar 

  2. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER (1993b) Depression: a neglected major illness. JClin Psych 54: 419–423

    CAS  Google Scholar 

  3. Angst J (1992) Epidemiology of depression. Psychopharmacology 106: S71–S74

    Article  PubMed  Google Scholar 

  4. Lepine J-P, Gastpar M, Mendlewicz J, Tylee A, on behalf of the DEPRES Steering Committee (1997) Depression in the community: the first panEuropean study DEPRES (Depression Research in European Society). Internat Clin Psychopharma 12: 19–29

    Article  CAS  Google Scholar 

  5. Pinder RM (1988) The benefits and risks of antidepressant drugs. Human Psychopharma 3: 73–86

    Article  Google Scholar 

  6. Pinder RM (1996) Why more antidepressants? Pharma News 3 (4): 11–14

    CAS  Google Scholar 

  7. Pinder RM, Wieringa JH (1993) Third-generation antidepressants. Med Res Rev 13: 259–325

    Article  PubMed  CAS  Google Scholar 

  8. Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. JPsychopharma 8: 238–249

    Article  CAS  Google Scholar 

  9. Schou M (1997) Forty years of lithium treatment. Arch Gen Psych 54: 9–13

    Article  CAS  Google Scholar 

  10. Post RM, Ketter TA, Denicoff K, Pazzaglia PJ, Leverich GS, Marangeii LB, Callahan AM, George MS, Frye MA (1996) The place of anticonvulsant therapy in bipolar illness. Psychopharma 128: 115–129

    Article  CAS  Google Scholar 

  11. Broekkamp CLE, Leysen D, Peeters PWMM, Pinder RM (1995) Prospects for improved antidepressants. J Med Chem 38: 4615–4633

    Article  PubMed  CAS  Google Scholar 

  12. Skolnick P (ed) (1997) Antidepressants. New pharmacological strategies. Humana Press, Totowa, New Jersey

    Google Scholar 

  13. Blier P, De Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharma Sci 15: 220–226

    Article  CAS  Google Scholar 

  14. Thase ME, Rush AJ, Kasper S, Nemeroff CB (1995) Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression 3: 152–168

    Google Scholar 

  15. Nemeroff CB (1997) Augmentation strategies in patients with refractory depression. Depression Anxiety 4: 169–181

    Article  CAS  Google Scholar 

  16. Artigas F, Romero L, De Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neuro Sci 19: 378–383

    Article  CAS  Google Scholar 

  17. Nelson JC, Mazure CM, Bowers MB, Jatiow PL (1991) A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psych 48: 303–307

    Article  CAS  Google Scholar 

  18. Dam J, Ryde O, Svejso J, Lauge N, Lauritzen B, Bech P (1998) Morning fluoxetine plus evening mianserin vs. morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 31: 1–7

    Article  Google Scholar 

  19. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY (1999) Pindolol and mianserin augment the antidepressant efficacy of fluoxetine in hospitalised major depressed patients even in those with treatment resistance. J Clin Psychopharma 19: 177–182

    Article  CAS  Google Scholar 

  20. Cappiello A, Oren D, Anand A, Berman R, Charney D (1998) Yohimbine plus fluoxetine combination for rapid treatment of depression. Abstract 36th Meeting of American College of Neuropsychopharmacology, Hawaii, 250

    Google Scholar 

  21. Pinder RM (1997) Designing a new generation of antidepressant drugs. Acta Psychiatrica Scandinavica 96 (Suppl. 391): 7–13

    Article  Google Scholar 

  22. Sambunaris A, Keppel Hesselink J, Pinder R, Panagides J, Stahl SM (1997) Development of new antidepressants. J Clin Psych 58 (Suppl. 6): 40–53

    CAS  Google Scholar 

  23. Nutt DJ (ed) (1977) Reboxetine: a selective noradrenaline reuptake inhibitor. Additional benefits to the depressed patient. J Psychopharma 11 (Suppl): S3–S47

    Google Scholar 

  24. Romero L, Bel N, Casanovas JM, Artigas F (1996) Two actions are better than one: avoiding self-inhibition of serotonergic neurons enhances the effects of serotonin uptake inhibitors. Internat Clin Psychopharma 11 (Suppl 4): 1–8

    Article  Google Scholar 

  25. Shader RL, Fogelman SM, Greenblatt DJ (1997) Newer antidepressants: hypotheses and evidence. J Clin Psychopharma 17: 1–3

    Article  CAS  Google Scholar 

  26. Stahl SM (1997) Are two antidepressant mechanisms better than one? J Clin Psych 58: 339–340

    Article  CAS  Google Scholar 

  27. Clerc GE, Ruimy P, Verdeau-Pailles J on behalf of the Venlafaxine French Inpatient Study Group (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. Internat Clin Psychopharma 9: 139–143

    Article  CAS  Google Scholar 

  28. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996) Milnacipran and selective serotonin reuptake inhibitors in major depression. Internat Clin Psychopharma 11 (Suppl 4): 41–46

    Article  Google Scholar 

  29. Wheatley D, Van Moffaert M, Timmerman L, Kremer CE for the Mirtazapine-Fluoxetine Study Group (1998) Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with major depression. J Clin Psych 59: 306–312

    Article  CAS  Google Scholar 

  30. Bianchi G, Caccia S, Della Vedova F, Garattini S (1988) The alpha-2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur J Pharmacol 151: 365–371

    Article  CAS  Google Scholar 

  31. Feiger AD (1996) A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 32: 659–665

    PubMed  CAS  Google Scholar 

  32. McGrath PJ, Stewart JW, Quitkin FM, Wager S, Jenkins SW, Archibald DG, Stringfellow JC, Robinson DS (1994) Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 14: 347–352

    Article  PubMed  CAS  Google Scholar 

  33. Cryan JF, Redmond AM, Kelly JP, Leonard BE (1997) The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat. Eur Neuropsychopharmacol 7: 109–114

    Article  PubMed  CAS  Google Scholar 

  34. Dugast L (1998) Is the potent 5-HT1A receptor agonist, alnespirone (S-20499), affecting dopaminergic systems in the rat brain? Eur JPharmacol 350: 171–180

    Article  CAS  Google Scholar 

  35. Costal! B, Domeney AM, Farre AJ, Kelly ME, Martinez L, Naylor RJ (1992) Profile of action of a novel ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. J Pharmacol Exp Ther 262: 90–98

    Google Scholar 

  36. Johansson L, Sohn D, Thorberg SO, Jackson DM, Kelder D, Larsson LG, Renyi L, Ross SB, Wallsten C, Eriksson H et al (1997) The pharmacological characterization of a novel selective 5-hydroxytryptaminelA receptor antagonist, NAD-299. J Pharmacol Exp Ther 283: 216–225

    PubMed  CAS  Google Scholar 

  37. Berendsen HH, Broekkamp CL (1994) Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure. Eur J Pharmacol 253: 83–89

    Article  PubMed  CAS  Google Scholar 

  38. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL et al (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913–924

    CAS  Google Scholar 

  39. Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, Wichmann J, Van Delft AM (1998) Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8: 161–168

    Article  PubMed  CAS  Google Scholar 

  40. Mellow AM, Lawler BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL (1990) Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients; initial experience with a serotonin agonist. Biol Psychiatry 28: 588–594

    Article  PubMed  CAS  Google Scholar 

  41. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemis DN, Blackburn TP (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609–620

    Article  PubMed  CAS  Google Scholar 

  42. Davis R, Whittington R, Bryson HM (1997) Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 53. 608–636

    Article  PubMed  CAS  Google Scholar 

  43. Bakish D, Hooper CL, Thornton MD, Wiens A, Miller CA, Thibaudeau CA (1997) Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Tnt Clin Psychopharmacol 12: 91–97

    Article  CAS  Google Scholar 

  44. D’Aquila P, Monleon S, Borsini F, Brain P, Willner P (1997) Anti-anhedonic actions of the novel serotonergic aagent flibanserin, a potential rapidly-acting antidepressant. Eur J Pharmacol 340: 121–132

    Article  PubMed  Google Scholar 

  45. Borsini F, Cesana R, Kelly J, Leonard BE, McNamara M, Richards J, Seiden L (1997) BIMT 17: a putative antidepressant with a fast onset of action? Psychopharmacology 134: 378–386

    Article  PubMed  CAS  Google Scholar 

  46. Montgomery SA (1997) Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11 Suppl4: S9–15

    CAS  Google Scholar 

  47. Trendelenburg AU, Wahl CA, Starke K (1996) Antagonists that differentiate between alpha(2A)- and alpha(2D)-adrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 353: 245–249

    Article  PubMed  CAS  Google Scholar 

  48. Firestone JA, Gerhardt GA, DeBernardis JF, McKelvy JF, Browning MD (1993) Actions of A-75200, a novel catecholamine uptake inhibitor, on norepinephrine uptake and release from bovine adrenal chromaffin cells. J Pharmacol Exp Ther 264: 1206–1210

    PubMed  CAS  Google Scholar 

  49. Hancock AA, Buckner SA, Giardina WJ, Brune ME, Lee JY, Morse PA, Oheim KW, Stansic DS, Warner RB, Kerkman DJ et al (1995) Preclinical pharmacological actions of (+/-)-(1’R*,3R*)-3-phenyl-1-[1’ 2’,3’,4’-tetrahydro-5’,6’-methylene-dioxy-l’-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. JPharmacol Exp Ther 272: 1160–1169

    CAS  Google Scholar 

  50. Satel SL, Nelson JC (1989) Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 50: 241–249

    PubMed  CAS  Google Scholar 

  51. Fibiger HC, Phillips AG (1981) Increased intracranial selfstimulation in rats after long-term administration of desipramine. Science 214: 683–685

    Article  PubMed  CAS  Google Scholar 

  52. Willner P (1997) The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 12 Suppl 3: S7–S14

    Article  PubMed  Google Scholar 

  53. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA (1994) Comparison of bupropion and trazadone for the treatment of major depression. J Clin Psychopharmacol 14: 170–179

    Article  PubMed  CAS  Google Scholar 

  54. Dalery J, Rochat C, Peyron E, Bernard G (1997) The efficacy and acceptability of amineptine vs. fluoxetine in major depression. Int Clin Psychopharmacol 12 Suppl 3: S35–S38

    Article  PubMed  Google Scholar 

  55. Garattini S (1997) Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review. Int Clin Psychopharmacol 12 Suppl 3: S15–S19

    Article  PubMed  Google Scholar 

  56. Maj J, Kolodziejczyk K, Rogoz Z, Skuza G (1997) Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. It. Effects on the 5-hydroxytryptamine system. Pharmacopsychiatry 30: 55–61

    Article  PubMed  CAS  Google Scholar 

  57. Grunder G, Wetzel H, Hammes E, Benkert O (1993) Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology 111:123–126

    Article  PubMed  CAS  Google Scholar 

  58. Kihara T, Ikeda M (1995) Effects of duloxetine, a new serotonin and norepinephrine inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272: 177–183

    PubMed  CAS  Google Scholar 

  59. Derivan A, Entsuah A, Kikta D (1995) Venlafaxine: measuring the onset of antidepressantaction. Psychopharmacology 131: 349–447

    Google Scholar 

  60. Stimme! GL, Dopheide JA, Stahl S (1997) Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacoptherapy 17: 10–21

    CAS  Google Scholar 

  61. Silvestre J, Grant A, Castaner J (1998) Sunepitron hydrochloride. Drugs of the Future 23: 161–165

    Article  CAS  Google Scholar 

  62. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ (1997) Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant mono-therapy. J Clin Psychiatry 58: 137–145

    Article  PubMed  CAS  Google Scholar 

  63. Cartier P, Lo M, Lo P, Richelson E, Atsumi M, Reynolds I, Sharma T (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrinc-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorganic & Medicinal Chemistry Letters 8: 487–492

    Article  Google Scholar 

  64. Holsboer F, Barden N (1996) Antidepressants and the hypothalamic pituitary adrenocortical regulation. Endocr Rev 17: 187–205

    PubMed  CAS  Google Scholar 

  65. Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review.Psychoneuroendocrinology 22 Suppl 1: S 125–132

    Google Scholar 

  66. Behan DP, Grigoriadis DE, Lovenberg T, Chalmers D, Heinrichs S, Liaw C, De Souza EB (1996) Neurobiology of corticotropin releasing factor (CRF) receptors and CRF binding protein: implications for the treatment of CNS disorders. Mol Psychiatry 1: 265–277

    PubMed  CAS  Google Scholar 

  67. Esposito G, Luparini MR (1997) Pivagabinc: a novel psychoactive drug. Arzneimittelforschung 47: 1306–1309

    PubMed  CAS  Google Scholar 

  68. Gold PW, Goodwin FK, Chrousos (1988) Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress. New Eng JMed 319: 413–420

    Article  CAS  Google Scholar 

  69. Martinet L, Guardiola-Lemaitre B, Mocaer E (1996) Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 54: 713–718

    Article  PubMed  CAS  Google Scholar 

  70. Kellner M, Yassouridis A, Manz B, Steiger A, Holsbooe F, Wiedemann K (1997) Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers - a potential link to low-melatonin syndrome in depression? Neuroendocrinology 65: 284–290

    Article  PubMed  CAS  Google Scholar 

  71. Kramer S, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E et al (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640–1645

    Article  PubMed  CAS  Google Scholar 

  72. Horger BA, Roth RH (1996) The role of mesoprefrontal dopamine neurons in stress. Crit Rev Neurobiol 10: 395–418

    Article  PubMed  CAS  Google Scholar 

  73. McBain CJ, Mayer ML (1994) N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 74: 723–760

    Article  PubMed  CAS  Google Scholar 

  74. Nowak G, Redmond A, McNamara M, Paul IA (1995) Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J Neurochem 64: 925–927

    Article  CAS  Google Scholar 

  75. Kim JJ, Foy MR, Thompson RF (1996) Behavioral stress modifies hippocampal plasticity through N-methyl-D-aspartate receptor activation. Proc Natl Acad Sci USA 93: 4750–4753

    Article  PubMed  CAS  Google Scholar 

  76. Loscher W, Honack D (1992) The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 215: 199–208

    Article  PubMed  CAS  Google Scholar 

  77. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P (1994) Adaptation of the N-Methyl-DAspartate receptor complex following chronic antidepressant treatments. JPharmacol Exp Ther 269: 95–102

    CAS  Google Scholar 

  78. Paul IA, Layer RT, Skolnick P, Nowak G (1993) Adaption of the N-Methyl-D-Aspartate receptor complex in rat front cortex following chronic treatment with electroconvulsive shock or imipramine. Eur J Pharmacol 247: 305–312

    Article  PubMed  CAS  Google Scholar 

  79. Nowak G, Li Y, Paul IA (1996) Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur J Pharmacol 295: 75–85

    Article  PubMed  CAS  Google Scholar 

  80. Maj J, Rogoz Z, Skuza G, Sowinska H (1992) The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonist, in the forced swimming test. Pol J Pharmacol Pharm 44: 337–346

    PubMed  CAS  Google Scholar 

  81. Maj J, Rogoz Z, Skuza G, Sowinska H (1992) Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur Neuropsychopharmacol 2: 37–41

    Article  PubMed  CAS  Google Scholar 

  82. Thomson AM (1990) Glycine is a coagonist at the NMDA receptor/channel complex. Prog Neurobiol 35: 53–74

    Article  PubMed  CAS  Google Scholar 

  83. Fossom LH, Basile AS, Skolnick P (1995) Sustained exposure to 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, alters N-methyl-D-aspartate receptor function and subunit composition. Mol Pharmacol 48: 981–987

    PubMed  CAS  Google Scholar 

  84. Papp M, Moryl E (1996) Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 316: 145–151

    Article  PubMed  CAS  Google Scholar 

  85. Heppenstall PA, Fleetwood-Walker SM (1997) The glycine site of the NMDA receptor contributes to the neurokinin 1 receptor agonist facilitation of NMDA receptor agonist-evoked activity in rat dorsal horn neurons. Brain Res 744: 235–245

    Article  PubMed  CAS  Google Scholar 

  86. Debonnel G (1993) Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J Psychiatry Neurosci 18: 157–172

    PubMed  CAS  Google Scholar 

  87. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V (1998) Cloning and functional characterisation of a sigma receptor from rat brain. J Neurochem 70: 922–931

    Article  PubMed  CAS  Google Scholar 

  88. Moebius FF, Bermoser K, Reiter RJ, Hanner M, Glossman H (1996) Yeast sterol C8–C7 isomerase: identification and characterization of a high-affinity binding site for enzyme inhibitors. Biochemistry 35: 16871–16878

    Article  PubMed  CAS  Google Scholar 

  89. Matsuno K, Kobayashi T, Tanaka MK, Mita S (1996) Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming tes. Eur J Pharmacol 312: 267–271

    Article  PubMed  CAS  Google Scholar 

  90. Rich CL, Spiker DG, Jewell SW, Neil JF, Black NA (1984) The efficiency of ECT: I. Response in depressive episodes. Psychiatric Res 11: 167–176

    Article  CAS  Google Scholar 

  91. Wu JC, Bunney WE Jr (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 147: 14–21

    CAS  Google Scholar 

  92. Delgado PL, Moreno FA, Potter R, Gelenberg AJ (1998) Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. In: M Briley, S Montgomery (eds): Antidepressant therapy at the dawn of the third millenium. Martin Dunitz Ltd, UK, 141–161

    Google Scholar 

  93. Davis KL, Hollister E, Overall J, Johnson A, Train K (1976) Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacologia 51: 23–27

    Article  CAS  Google Scholar 

  94. Malek-Ahmadi P (1996) Neuropsychiatrie aspects of cytokines research: an overview. Neurosci Biobehav Rev 20: 359–365

    Article  PubMed  CAS  Google Scholar 

  95. Weigers G, Reul JMHM (1998) Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Ti PS 19: 317–321

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Janssen Research Foundation, Turnhoutsweweg 30, Beerse, 2340, Belgium

    John S. Andrews

  2. Organon Inc, 375 Mount Pleasant Avenue, West Orange, New Jersey, 07059, USA

    Roger M. Pinder

Authors
  1. John S. Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger M. Pinder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmacology Department, University College Galway, Galway, Ireland

    Brian E. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Andrews, J.S., Pinder, R.M. (2001). Chemistry and pharmacology of novel antidepressants. In: Leonard, B.E. (eds) Antidepressants. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8344-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8344-3_9

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9526-2

  • Online ISBN: 978-3-0348-8344-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation